Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

In Silico Prediction and In Vitro Assessment of Multifunctional Properties of Postbiotics Obtained From Two Probiotic Bacteria

  • 2019-07-06
  • Probiotics and Antimicrobial Proteins 12(2)
    • J. E. Aguilar-Toalá
    • F. Hall
    • U. Urbizo-Reyes
    • H. García
    • B. Vallejo‐Cordoba
    • A. F. González-Córdova
    • A. Hernández-Mendoza
    • A. Liceaga

Abstract

In this study, a global metabolite profile using Raman spectroscopy analysis was obtained in order to predict, by an in silico prediction of activity spectra for substance approach, the bioactivities of the intracellular content (IC) and cell wall (CW) fractions obtained from Lactobacillus casei CRL 431 and Bacillus coagulans GBI-30 strains. Additionally, multifunctional in vitro bioactivity of IC and CW fractions was also assessed. The metabolite profile revealed a variety of compounds (fatty acids, amino acids, coenzyme, protein, amino sugars), with significant probable activities (Pa > 0.7) as immune-stimulant, anti-inflammatory, neuroprotective, antiproliferative, immunomodulator, and antineoplastic, among others. Moreover, in vitro assays exhibited that both IC and CW fractions presented angiotensin-converting enzyme-inhibitory (> 90%), chelating (> 79%), and antioxidant (ca. 22-57 cellular antioxidant activity units) activities. Our findings based on in silico and in vitro analyses suggest that L. casei CRL 431 and B. coagulans GBI-30 strains appear to be promising sources of postbiotics and may impart health benefits by their multifunctional properties.

Keywords: In silico prediction; Lactobacillus; Multifunctional bioactivity; Postbiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus coagulans GBI-30, 6086Enhanced Chelation AbilityBeneficial
Large
Bacillus coagulans GBI-30, 6086Enhanced Immune FunctionBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Improved NeuroprotectionBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Increased Antioxidant ActivityBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Increased Immune FunctionBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Reduced Angiotensin I-Converting Enzyme ActivityBeneficial
Large
Bacillus coagulans GBI-30, 6086Reduced Cancer Cell ProliferationBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Reduced InflammationBeneficial
Moderate
Back to top